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Genetic matching potentially provides a means to alleviate the effects of incomplete Mendelian
randomization in population-based gene–disease association studies. We therefore evaluated the genetic-
matched pair study design on the basis of genome-wide SNP data (309 790 markers; Affymetrix GeneChip
Human Mapping 500K Array) from 2457 individuals, sampled at 23 different recruitment sites across
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Europe. Using pair-wise identity-by-state (IBS) as a matching criterion, we tried to derive a subset of
markers that would allow identification of the best overall matching (BOM) partner for a given individual,
based on the IBS status for the subset alone. However, our results suggest that, by following this approach,
the prediction accuracy is only notably improved by the first 20 markers selected, and increases
proportionally to the marker number thereafter. Furthermore, in a considerable proportion of cases
(76.0%), the BOM of a given individual, based on the complete marker set, came from a different
recruitment site than the individual itself. A second marker set, specifically selected for ancestry sensitivity
using singular value decomposition, performed even more poorly and was no more capable of predicting
the BOM than randomly chosen subsets. This leads us to conclude that, at least in Europe, the utility of the
genetic-matched pair study design depends critically on the availability of comprehensive genotype
information for both cases and controls.
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Introduction
In both classical epidemiology and clinical research,
potential confounders are usually controlled for by one
of two different means, matching or randomization. In
genetic studies, however, including the large number of
genome-wide association (GWA) studies that have recently
been published,1 – 3 only so-called ‘Mendelian’ randomiza-
tion has been employed to control for genetic confoun-
ders, whereas matching by genotype has not played an
important role.4 Nevertheless, there has always been some
awareness among genetic epidemiologists that Mendelian
randomization may fail, thereby leading to false positive
reports of disease genes or to biased effect size estimates.5
One possible cause of such failure may be systematic
differences in terms of the rate at which individuals with a
particular phenotype or genotype are sampled from
genetically distinct populations. Therefore, two statistical
methods to retrospectively rectify genetic imbalances in
case-control studies were developed in the late 1990s, both
of which rely upon genotyping loci that are unrelated to
the genetic variants under study (ie unlinked and not in
linkage disequilibrium). The ‘genomic control’ approach6
uses marker genotypes to correct the employed test
statistic, whereas ‘structured association’7 infers the num-
ber of populations represented in a sample, and then
assigns each individual to one of these populations with a
certain probability.
With the possibility to effectively genotype large num-
bers of single nucleotide polymorphisms (SNPs) in large
numbers of individuals, using microarray technology,8 the
effects of imperfect Mendelian randomization can, in
principle, also be alleviated by genetic matching. If
individuals from different samples such as cases and
controls were as closely matched as possible in terms of
their identity-by-state (IBS) status at a large number of
SNPs, it may be surmised that most systematic population
genetic differences would be eliminated between the
ensuing sub samples. However, genetic matching would
have to be based on markers from outside the genomic
region under study to avoid over-matching. This implies
that, in practise, repeated matching may be necessary if
multiple or even GWA assessments are due. In any case,
genetic matching could of course be accomplished effi-
ciently with the use of genome-wide microarray data, but
such a costly strategy may not be necessary if a set of ‘best
genetic match’ (BGM) markers could be established in
advance that are capable of capturing the major population
genetic characteristics of relevant extant populations.
Once a set of BGM markers has been found, it can be used
in two ways: either to retrospectively confirm whether two
samples of interest were genetically well-matched or to
select members of matched samples prospectively, before
any additional genotyping.
Recruitment of phenotypically well-characterized
control samples is one of the major bottlenecks of genetic
epidemiological and pharmacogenetic research. The use of
common controls across different association studies has
proven to be an efficient solution to this problem,
pioneered at a local level by the Wellcome Trust Case
Control Consortium (WTCCC),3 and since adopted, for
example, by the US-American Genetic Association Information
Network (GAIN)1 and the German National Genome
Research Network (‘Nationales Genomforschungsnetz’,
NGFN).9 However, the number and geographical distribution
of control samples required for the common controls approach
to be feasible at a broader geographical level are currently
unknown.
In the present study, we investigated three issues related
to the genetic-matched pair study design, using genome-
wide SNP data from across Europe: (1) the prospects of
identifying a small subset of SNPs that accurately predict
the ‘best’ genome-wide matching partner of a given
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individual, (2) the distribution of ‘best’ genetic-matching
partners between the European subpopulations and (3) the
inter-individual variability in terms of the uniqueness of
the ‘best’ genetic-matching partner. To this end, we
analyzed the genotypes of 309 790 markers obtained from
the GeneChip Human Mapping 500K Array Set in 2457
individuals, ascertained at one of 23 recruitment sites. The
European population is important in this context, not only
because of the historical interest in these people and their
descendants in the Americas, Australia and elsewhere, but
also because they are a major focus of both genetic
epidemiological and pharmacogenetic research.1,3
Material and methods
Samples, genotyping and quality control
The GeneChip Human Mapping 500K Array (Affymetrix)
was used to genotype 500 568 SNPs in 2514 individuals
from 23 different sampling sites (henceforth, termed
‘subpopulations’), distributed over 20 different European
countries. Subpopulation sizes ranged from 12 to 500
individuals (Table 1). Sex ratios differed markedly between
subpopulations, with some comprising only females or
males, respectively. Genotyping was carried out at six
different facilities. For further details, see Lao et al.10
Array-based SNP genotypes were subjected to stringent
quality control as described earlier.10 Briefly, markers,
which had a genotype call rateZ93%, were monomorphic,
located on the X chromosome or had a per marker call rate
r90% in at least one genotyping facility were excluded, as
were those showing a significant (Po0.05) deviation from
Hardy–Weinberg equilibrium (HWE) in at least one
subpopulation. Individuals deemed genetic outliers to
their subpopulation of origin, based on low average IBS
to the remaining individuals, were omitted from the
respective subpopulation. In total, quality control left
2457 individuals (97.6%) and 309 790 markers (62.4%)
for inclusion in subsequent analyses. The set of quality
controlled markers will henceforth be referred to as marker
set C. Ascertainment of a marker set for genetic matching
was carried out with internal validation, using 2/3 of the
members of each subpopulation (ie, 1638 randomly chosen
individuals) as the training set, and using the remainder
(819 individuals) as the validation set (Table 1).
All data were stored as either flat files or in a customized
database with an interface to the R statistical software. All
data analysis, except for the IBS estimation, was done in R
version 2.4.111 using customized scripts. IBS calculations
and selection of marker sets were carried out using custom
Cþþ programs. All software is available from the authors
on request.
Best genetic match marker set
For the ascertainment of a marker subset M of C that would
allow us to identify ‘best’ genetic-matching partners, we
will use a set-specific criterion, D(M) that is related to the
IBS between given individuals and their matching partners,
as selected on the basis of M (see below). In this context, we
will use the term ‘best overall match’ (BOM) to denote that
individual or group of individuals who maximize
the average pair-wise IBS with the individual of interest
for the complete marker set C. Ideally, we would want to
ascertain a subset of markers that consistently lead to
the selection of matching partners with an IBS with the
reference individual that is close to the IBS between
the reference individual and its BOM.
More formally, if the genotype (g), of a given SNP is
encoded by the dose of one of its two alleles (ie, as 0, 1 or
2), then the IBS between any two individuals x and y equals
1|g(x)g(y)|/2 for that SNP. Here, g(x) and g(y) denote the
genotypes of x and y, respectively. For a marker set M, let
iM(x,y) be the average IBS, taken over all markers in M, and
let iM(x) denote the maximum iM(x,y), taken over all
individuals y other than x. Finally, if MDN are two nested
marker sets, let iM,N(x) be the average iN(x,y) taken over all y
for which iM(x,y)¼ iM(x). For a marker set MDC, D(M) is
defined as the average difference |iC(x)iM,C(x)|, taken over
all individuals x and weighted by the inverse of the size of
the subpopulation to which x belongs.
We used forward selection from marker set C to ascertain
marker sets that successively minimized the D criterion.
The ensuing marker sets will be referred to as the best
genetic match (BGM) marker sets. Upper and lower base-
lines for D were computed as follows. The upper baseline
was obtained from randomly chosen marker sets of varying
size (10–100 in steps of 10), with 1000 sets sampled for
each set size value. The lower baseline was obtained from
marker sets that theoretically should have captured most of
the genetic variation present in the individuals under
study, ie sets for which any additional marker would have
been in strong linkage disequilibrium with the markers
already included. Each chromosome was thus divided into
bins of 20 kb, based on the mean swept radius of 500 kb
estimated for the European population.12,13 The swept
radius is the distance at which the average association
between two markers, measured by r2, is reduced to
approximately one-third (more precisely, e1) of its initial
value. A bin size of 20 kb therefore ensures an average r2 of
e10/500¼0.98 between markers in the bin. Markers were
then randomly selected from bins, one at a time, and D
calculated for the resulting marker set. The described
selection process was repeated 1000 times and the mean
D value taken as the lower baseline, ie the expectation of D
at r2-based saturation.
Ancestry-sensitive marker set
To compare the BGM set, which focuses on inter-individual
genetic variation with a marker set that was ascertained
with the aim to highlight inter-population variation, we
generated an ancestry-sensitive marker (ASM) set using the
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singular value decomposition (SVD) method with redun-
dant marker reduction described by Paschou et al.14,15
Global allele frequencies were used to interpolate missing
data as suggested by the authors. Some 228 individuals
were eliminated from the training set during PCA analysis
with Eigensoft216 using the standard criterion of having an
ancestry coefficient 46 standard deviations in at least one
of the eigenvector axes. SVD was carried out with SVDLIBC
(version 1.34, http://tedlab.mit.edu/~dr/SVDLIBC), a C
library based on the SVDPACK library.17 Rank-revealing
QR matrix decomposition was carried out in Octave
version 2.0.1718 to reduce the redundancy of the first
5000 markers, ordered by the first SVD eigenvector. This
resulted in a set of the same size (ie 100 markers) as the
BGM set.
Distribution of best genetic match pairs
A count matrix was generated that contains, for each pair
of subpopulations, the number of times an individual in
the first subpopulation had their BOM in the second
population. Cell counts were tested for a deviation from
the null hypothesis that BOMs were drawn randomly from
subpopulations using a two-tailed exact test as implemen-
ted in the R routine binom.test. A plot of directed graphs
representing the relationships between individuals and
their BOMs was generated using Graphviz.19
False positive rates
Thresholds for the false positive rates of population-based
gene–disease associations in Europe were determined from
contrived case-control experiments, using PLINK version
1.0320 on all markers in set C (Fisher’s exact test on allele
frequencies). These mock studies were carried out for all
pair-wise combinations of subpopulations, each time
labeling one subpopulation as ‘cases’ and the other as
‘controls’. The percentage of markers with P-values o0.05
was reported. As the variance of the P-value is inversely
related to sample size, false positive rates were not
estimated for subpopulations with sample sizes o20 (PT,
HU and RO; see Table 1 for subpopulation abbreviations).
Results
Best genetic match and ancestry sensitive marker sets
Two subsets of markers (BGM and ASM) were ascertained
from the complete marker set using either IBS-based
forward selection or SVD with redundant marker reduc-
tion, respectively. As the decrease in D as a function of
marker set size levelled off very rapidly (see Figure 1), BGM
marker selection was terminated at 100 SNPs (Supplemen-
tary Table 1). For the sake of comparability, the ASM set was
chosen so as to contain the same number of markers as the
BGM set (Supplementary Table 2). Interestingly, the top
5000 markers of the provisional ASM set included various
SNPs annotated to genes known to stratify the European
Table 1 European subpopulation summary statistics
Subpopulation Code No. samples Final no. samples No. training
Norway (Frde) NO 52 52 (0.63) 35
Sweden (Uppsala) SE 50 46 (1.00) 31
Finland (Helsinki) FI 47 47 (0.43) 31
Ireland IE 37 35 (0.80) 23
UK (London) UK 197 194 (0.90) 129
Denmark (Copenhagen) DK 60 59 (0.56) 39
Netherlands (Rotterdam) NL 292 280 (0.00) 187
Germany I (Kiel) DE1 500 494 (0.52) 329
Germany II (Augsburg) DE2 500 489 (0.51) 326
Austria (Tyrol) AT 50 50 (1.00) 33
Switzerland (Lausanne) CH 134 133 (0.44) 89
France (Lyon) FR 50 50 (0.68) 33
Portugal PT 16 16 (0.44) 11
Spain I ES1 83 81 (0.51) 54
Spain II (Barcelona) ES2 48 47 (0.43) 31
Italy I IT1 107 106 (0.58) 71
Italy II (Marche) IT2 50 49 (1.00) 33
Former Yugoslavia YU 58 55 (0.65) 37
Northern Greece EL 51 51 (0.59) 34
Hungary HU 17 17 (0.35) 11
Romania RO 12 12 (0.50) 8
Poland (Warsaw) PO 50 49 (1.00) 33
Czech Republic (Prague) CZ 53 45 (0.51) 30
Total 2514 2457 1638
Subpopulation, site of sample origin, with more specific location details given in parentheses; No. samples, total number of samples genotyped; Final
no. samples, number of samples that passed stringent quality control, with proportion of males in parenthesis (for details, see text); No. training, size of
the training set used for marker selection.
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gene pool as a result of recent positive selection acting
differently in different geographic regions, including
HERC221 (ranked 7), OCA222 (ranked 33), LCT23 (ranked
262) and TYRP124 (ranked 1138).
A graphical representation of the forward selection
process leading to the BGM set is provided in Figure 1. In
the validation set, the D criterion decreased byB10% until
it levelled off at B20 markers, and decreased only margin-
ally thereafter. Although forward selection on the training
set showed a promising reduction in D value, the validation
D for the 100 top markers comprising the BMG set was still
at 9.3 105, which is 14.3% lower than the upper
(random) baseline but exceeds the lower baseline of
1.5105 by a factor of six. This implies that the
genome-wide similarity of two European individuals is
hard to predict with sufficient accuracy on the basis of a
small, specifically selected marker set, and that the little
benefit that can be gained in this respect already arises
from 100 markers or even fewer. By comparison, the
capacity of the ASM set for BOM prediction was found to
be indistinguishable from the upper (random) baseline, ie,
it performed no better than randomly drawn marker sets.
Distribution of best overall matches (BOMs)
A significant amount of genetic similarity between the
European subpopulations is revealed by an assessment of
the subpopulation of origin of BOMs (Table 2). In a
considerable proportion of cases (1868/2457 or 76.0%),
the BOM of a given individual belonged to a different
subpopulation than the individual itself. That this was
particularly so when individuals or BOMs came from
subpopulations with large sample sizes (DE1, DE2 and
NL) was presumably due to the wider range of genetic
diversity captured by these samples, but may also reflect
their concurrent geographic location in central Europe. On
the other hand, for some relatively isolated subpopulations
(FI and IT2) the source of the BOM was mostly the
subpopulation itself, reflecting their separation also seen
in genetic barrier analysis and, in the case of the Finns,
principle component analysis.10 Closer inspection at the
individual level revealed that some individuals were
disproportionately more often selected as BOMs than
others (Figure 2). Thus, of the 2457 individuals examined,
1860 (75.7%) were never deemed a BOM at all. This is
significantly higher than the expected number (1553.3,
63.2%) if BOMs were drawn at random (w2¼165.1, 1 df,
Po0.001). At the same time, 120 individuals were chosen
as BOMs at least five times, which is a significant excess
over expectation (9.0, 0.36%, w2¼1401.9, 1 df, Po0.001).
The subpopulation of origin of the 10 most frequently
ascertained BOMs was generally among those central
Europeans who also had the largest sample size (DE1 five,
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Figure 1 IBS-based forward selection of best genetic match (BGM) marker sets. The upper baseline for D is illustrated by box-whisker plots, each
generated from 1000 random selections of a marker set of given size. The lower baseline for D (dotted line) is provided by a marker set for which any
additional markers could be expected to be in strong linkage disequilibrium (r240.98) with at least one marker already included in that set (for details,
see text). Selection of the BGM marker sets is depicted by a solid line; the performance of ASM sets of various sizes is illustrated by a dashed line. All D
values were calculated from the validation set of individuals. The training set D values obtained for the BGM marker sets are included for reference
(dash-dotted line).
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DE2 two and NL one), with the notable exception of DK
(59 individuals, yet holding two of the top 10 positions;
Figure 2). Interestingly, barring of the 10 most frequently
chosen BOMs left the number of times the BOM was
found outside the subpopulation of origin of the individual
of interest virtually unchanged (1862/2457 or 75.8%,
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Figure 2 Distribution of the number of times an individual was deemed a BOM. The observed distribution is marked by circles. Also included is a
Poisson distribution with the same mean as the sample mean (marked by squares), which approximately corresponds to the theoretical expectation if
best overall matching (BOM) were selected at random. The codes of the subpopulation of origin of the 10 most frequently selected BOMs are given at
the upper right edge of the plot.
Table 2 Count matrix of BOM (best overall match) affiliation
NO SE FI IE UK DK NL DE1 DE2 AT CH FR PT ES1 ES2 IT1 IT2 YU EL HU RO PO CZ Total
NO 8 2 0 0 0 0 3 25 7 0 0 0 0 0 0 0 3 0 0 0 0 4 0 52
SE 6 1 0 0 2 2 4 22 5 0 2 0 0 0 0 0 2 0 0 0 0 0 0 46
FI 1 0 39 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 47
IE 1 0 0 4 12 3 3 3 3 0 0 2 0 0 0 0 4 0 0 0 0 0 0 35
UK 2 0 0 8 27 23 40 62 15 0 1 3 0 0 0 0 10 1 0 0 0 2 0 194
DK 1 0 0 0 0 10 13 23 7 0 0 0 0 0 0 0 2 0 0 0 0 3 0 59
NL 4 1 0 1 14 45 94 79 16 0 3 1 0 0 0 0 8 0 1 0 0 11 2 280
DE1 19 1 0 4 21 74 60 230 54 0 4 1 0 0 0 0 10 0 0 0 0 16 0 494
DE2 9 0 0 5 24 68 83 179 90 3 10 1 0 0 0 0 8 0 0 0 0 9 0 489
AT 0 0 0 0 3 8 7 15 13 0 0 0 0 0 0 0 3 0 0 0 0 1 0 50
CH 2 1 0 1 18 15 26 36 20 2 8 1 0 0 0 0 1 0 0 0 0 2 0 133
FR 0 0 0 1 3 4 11 16 8 0 1 2 0 0 0 0 1 1 0 0 0 2 0 50
PT 1 0 0 0 0 2 3 5 2 0 1 1 0 1 0 0 0 0 0 0 0 0 0 16
ES1 1 1 0 1 9 6 16 21 8 1 5 8 0 0 0 1 1 0 0 0 0 2 0 81
ES2 1 1 0 0 4 3 8 6 6 0 3 3 0 0 9 2 0 0 1 0 0 0 0 47
IT1 1 2 0 1 6 3 19 28 15 2 10 5 0 0 2 5 0 2 2 0 0 1 2 106
IT2 2 0 0 0 0 1 3 9 1 0 0 0 0 0 0 0 33 0 0 0 0 0 0 49
YU 3 1 0 0 4 0 8 20 7 0 1 0 0 0 0 0 1 10 0 0 0 0 0 55
EL 2 2 0 0 2 1 7 17 8 3 1 0 0 0 0 1 0 0 7 0 0 0 0 51
HU 1 0 0 0 1 2 4 8 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 17
RO 0 0 0 0 1 2 1 2 2 0 2 1 0 0 0 1 0 0 0 0 0 0 0 12
PO 3 0 0 0 1 13 2 16 5 0 0 0 0 0 0 0 0 0 0 0 0 8 1 49
CZ 0 0 0 2 2 3 11 15 3 1 1 1 0 1 0 0 1 0 0 0 0 0 4 45
Total 68 13 39 28 154 288 426 841 295 12 53 31 0 2 11 10 88 14 11 0 0 64 9
Row, subpopulation of origin of reference individual; Column, subpopulation of origin of BOM of reference individual.
Underlined values are significantly higher than random expectation (P-valuer0.05), bold values are statistically significant after Bonferroni correction
(FWERr0.05).
Genetic-matched pair study design in Europe
TT Lu et al
972
European Journal of Human Genetics
Supplementary Table 4). A graphical representation of the
BOM relationships between individuals is provided in a
directed graph illustrating the complexity of networks of
matches (Figure 3).
False positive rates
Although it is admittedly unlikely that a researcher would
actually carry out a population-based gene–disease associa-
tion study in which cases and controls were sampled from
different countries, without adjusting for population origin
in one way or another, measurement of the false positive
rates expected from such undertaking is of general interest
as a gauge of the magnitude of stratification pertaining in
the European population. Mock false positive rates for pairs
of subpopulations (Supplementary Table 3) ranged from
0.039 (CZ and PO) to 0.208 (DE1 and IT1), with a median of
0.070. Subpopulations sampled from the same political
country often had false positive rates indicative of little or
no population stratification, although this was not always
the case (DE1–DE2: 0.089). Many neighboring countries
also had false positive rates close to those expected under
the null hypothesis, indicating the absence of major
population differences as well (eg UK-IE: 0.042, NL-DK:
0.051, EL-YU: 0.047, CH-AT: 0.039, FR-DE2: 0.051).
Discussion
This is the first study to evaluate the genetic (ie, IBS-)
matched pair study design with genome-wide SNP data of a
large number of European individuals from across the
continent. The high number of best genetic-matching
partners found in different subpopulations corroborates
earlier reports of a considerable amount of genetic similarity
between the European subpopulations,4,10,14,25–27 parti-
cularly those in close geographic proximity. The surprising
inter-individual variability observed in terms of the number
of times a person was chosen as the best genetic-matching
partner of others does not necessarily imply that the
relationship between genetic and geographic distance in a
Figure 3 Directed graph illustrating the best overall matching (BOM) relationships between individuals. Circles represent individuals (2457 total)
and arrows point towards the respective BOM. The most frequently selected BOM (centre of the plot) was selected for 187 individuals.
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given sample hinges on a small number of people. Thus,
when the most frequently chosen matching partners were
barred in our analysis, the proportion of best matches found
outside the subpopulation of origin of the respective index
person remained virtually unchanged.
We observed that the best genetic-matching partner for a
genome-wide marker set such as the Affymetrix GeneChip
Human Mapping 500K Array cannot be predicted from a
small, specifically selected subset of markers alone, but that
the information required to make such predictions is
distributed evenly across all markers. This leads us to
conclude that, at least in Europe, the utility of the genetic-
matched pair study design depends critically on the
availability of comprehensive genotype information for
both cases and controls. In practise, this would mean that
shared controls should ideally be genotyped for all relevant
genome-wide marker sets, thereby allowing the chromo-
some-specific choice of best matching partners for given
case individuals on the basis of the remainder of the
genome.
A distinction must obviously be made between ASM,
collections of which have been described in recent
papers,14,25 – 28 and the BGM marker set that we attempted
to generate. As the genetic within-subpopulation variation
in Europe is much greater than the between-subpopulation
variation, it is not unlikely for any two individuals from
different subpopulations to be genetically more similar to
each other than any two individuals from the same
subpopulation. In this sense, an ASM marker set consists
of markers that differentiate subpopulations, whereas a
BGM marker set should contain variants that highlight
genetic similarity at the individual level. Although the two
concepts are complimentary, the marker sets fit to each
task need not be the same, and the existence of one set
does not necessitate the existence of the other. Obviously,
markers that arose on early branches of the corresponding,
region-specific coalescence tree of the extant Europeans
would provide good ASM, but they cannot at the same time
identify nearest neighbors at the tips of the tree. Such
identification requires a much higher resolution of the tree
topology, and therefore many more markers. Conse-
quently, no adequately sized BGM set could be constructed
in our study and the ASM set selected with established
methodology was no more capable of identifying the best
genetic-matching partner of an individual than a randomly
chosen marker set.
Recently, two independent applications of genetic
matching have been reported in the context of GWA
studies,4,29 both of which relied on information derived
from PCA of genotypes to match individuals. In the first
study, using US-American type 1 diabetes patients and
German controls, Luca et al4 carried out ‘full’ matching
wherein matches consist of clusters of individuals that
contain at least one case and one control. Matching was
based upon a distance measure with the top eigenvectors as
coordinates, weighted by the eigenvalues to exaggerate
differences in dimensions of greater importance. In the
second study, Heath et al29 undertook a PCA on a large pan-
European group of individuals and proposed a method to
predict the population affiliation of a sample of unknown
origin from the eigenvector matrix of its genotypes. As
both methods are likely to reduce spurious genetic
differences between cases and controls in disease associa-
tion studies, basing their matching criteria on eigenvectors
from PCA is strongly reminiscent of selecting ASM.
However, as we have shown above, matching with ASM is
less efficient than best overall genetic matching particu-
larly in Europe, where the within-subpopulation genetic
variation is known to be much greater than the between-
subpopulation variation. Indeed, the conclusion by Luca
et al4 that some individuals remain ‘unmatchable’ by their
approach is not surprising bearing in mind that ASM can
only capture a miniscule proportion of the actual inter-
individual genetic differences in a given population.
The false positive rates derived in our study from mock
genetic case-control experiments represent an upper limit
to the likely consequences of sharing samples in continent-
wide scientific collaborations. In this respect, the rate
estimates also rationalize collaborative genetic epidemio-
logical and pharmacogenetic research in Europe; from the
data we have compiled, it seems as if research projects
combining cases from neighboring subpopulations and
matching them against common control samples, such as
those provided by the WTCCC,3 GAIN1 and NGFN,9 may
indeed be valid.
In conclusion, we found that the pattern of pair-wise
genetic matching in the European population was more
complex than anticipated. Best genetic matches occurred
frequently across the continent in our study, and dispro-
portionately often involved a small group of individuals.
Ascertainment of a subset of markers that accurately
predicts best overall genetic matches turned out to be
infeasible.
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